Health Care & Life Sciences » Pharmaceuticals | Corium International Inc.

Corium International Inc. | Cash Flow

Fiscal year is October-September. All values USD Thousands.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
13,877.00
9,912.00
28,450.00
36,703.00
47,793.00
Depreciation, Depletion & Amortization
2,433.00
2,777.00
2,637.00
2,514.00
1,792.00
Other Funds
8,141.00
4,586.00
2,916.00
5,459.00
5,580.00
Funds from Operations
3,303.00
11,721.00
22,897.00
28,730.00
40,421.00
Changes in Working Capital
2,321.00
370.00
2,182.00
364.00
3,231.00
Net Operating Cash Flow
982.00
11,351.00
20,715.00
29,094.00
37,190.00
Capital Expenditures
7,956.00
3,805.00
1,749.00
2,327.00
3,183.00
Sale of Fixed Assets & Businesses
17.00
12.00
11.00
-
-
Purchase/Sale of Investments
-
-
-
666.00
666.00
Net Investing Cash Flow
7,939.00
3,693.00
1,738.00
2,993.00
2,517.00
Issuance/Reduction of Debt, Net
10,244.00
5,410.00
9,018.00
1,097.00
150.00
Net Financing Cash Flow
10,257.00
37,858.00
58,276.00
298.00
57,340.00
Net Change in Cash
1,336.00
22,814.00
35,823.00
32,385.00
17,633.00
Free Cash Flow
8,145.00
14,572.00
21,688.00
30,543.00
39,470.00
Other Sources
-
100.00
-
-
-
Change in Capital Stock
13.00
43,268.00
49,258.00
799.00
57,490.00

About Corium International

View Profile
Address
235 Constitution Drive
Menlo Park California 94025
United States
Employees -
Website http://www.coriumgroup.com
Updated 09/14/2018
Corium International, Inc. is a commercial stage biopharmaceutical company, which develops, manufactures and commercializes pharmaceutical products. The company development platforms enable transdermal delivery of large molecules or biologics, including vaccines, peptides and proteins, as well as small molecules that are otherwise difficult to deliver in a transdermal dosage form. The firm offers its products under the brands Corplex and MicroCor.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.